Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope

Actiphage – Confidence
to test for active TB

Loading...

Call to action

One quarter of the world’s population is infected with latent tuberculosis (LTBI), also known as inactive tuberculosis. One in ten people with LTBI will progress to active TB disease.

It is essential to develop newer diagnostic tests with significantly increased predictive value for the development of active disease among those who are infected than the currently available tests for LTBI (WHO, 2017).

Our mission

At PBD Biotech, our mission is to support the scale-up of latent tuberculosis test-and-treat campaigns with Actiphage to achieve the goals of the WHO End TB strategy. Leveraging Actiphage’s unique role in detecting active TB, PBD aims to drive innovation in the novel uses for TB screening and drug management.

AACC webinar “Phage-Based Laboratory Diagnostics Role in the Detection of Tuberculosis” 19th April 2023

Latest

Loading...
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics
March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics
March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
PCR bead

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain
March 17, 2023
Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold...
PCR bead

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain
March 17, 2023
Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR...

Actiphage TB test patent extended to West Africa
February 24, 2023
PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.

Actiphage TB test patent extended to West Africa
February 24, 2023
PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair
January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair
January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
1 2 3 4

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house